Development and validation of an in vitroein vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations

Journal of Food and Drug Analysis

Volumn 22, Issue 2, 2014, Pages 257-263

  Cheng, Chinhwa ^a,b   Wu, Pao Chu ^c   Lee, Hsin Ya ^c   Hsu, Kuang Yang ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b Medical and Pharmaceutical Technology and Development Center   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Extended release dosage; IVIVC; Propranolol

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MICROCRYSTALLINE CELLULOSE; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BEAGLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISSOLUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG SCREENING; EEXTENDED RELEASE DOSAGE FORMULATION; ELIMINATION RATE CONSTANT; FEASIBILITY STUDY; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; PHARMACOLOGICAL PARAMETERS; PREDICTION; VALIDATION STUDY; VOLUME OF DISTRIBUTION;

EID: 84914669549     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfda.2013.09.016     Document Type: Article

References (18)

1. Center for Drug Evaluation and Research (CDER), USFDA. Guidance for industrydextended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations; 1997.
2. Center for Drug Evaluation and Research (CDER), USFDA. Guidance for industrydSUPAC-MR: modified release solid oral dosage forms: Scale-up and postapproval changes: chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation; 1997.
3. Eddington ND, Ashraf M, Augsburger LL, et al. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets. Pharm Dev Technol 1998;3:535-47.
4. Lu Y, Kim S, Park K. In vitro-in vivo correlation: Perspectives on model development. Int J Pharm 2011;418:142-8.
5. Hayes S, Dunne A, Smart T, et al. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC). J Pharm Sci 2004;93:571-81.
6. Emami J. In vitro-in vivo correlation: from theory to applications. J Pharm Pharm Sci 2006;9:169-89.
7. Mahayni H, Rekhi GS, Uppoor RS, et al. Evaluation of "external" predictability of an in vitro-in vivo correlation for an extended-release formulation containing metoprolol tartrate. J Pharm Sci 2000;89:1354-61.
8. Mandal U, Ray KK, Gowda V, et al. In-vitro and in-vivo correlation for two gliclazide extended-release tablets. J Pharm Pharmacol 2007;59:971-6.
9. Mendyk A, Tuszynski PK, Polak S, et al. Generalized in vitroin vivo relationship (IVIVR) model based on artificial neural networks. Drug Des Devel Ther 2013;7:223-32.
10. Sirisuth N, Eddington ND. The influence of first pass metabolism on the development and validation of an IVIVC for metoprolol extended release tablets. Eur J Pharm Biopharm 2002;53:301-9.
11. Huang YB, Tsai YH, Yang WC, et al. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm 2004;58:607-14.
12. Semple HA, Xia F. Simplified high-performance liquid chromatographic method for propranolol and five metabolites in liver perfusate, rat serum and dog plasma. J Chromatogr B Biomed Appl 1994;655:293-9.
13. Center for Drug Evaluation and Research (CDER), USFDA. Guidance for industryddissolution testing of immediate release and solid oral dosage forms; 1997.
14. Dutta S, Qiu Y, Samara E, et al. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC). J Pharm Sci 2005;94:1949-56.
15. Chen ML, Jackson AJ. The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect. Pharm Res 1991;8:25-32.
16. Chen ML, Jackson AJ. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect. Pharm Res 1995;12:700-8.
17. Jackson AJ. The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect. Pharm Res 2000;17:1432-6.
18. Keller F, Kunzendorf U, Walz G, et al. Saturable first-pass kinetics of propranolol. J Clin Pharmacol 1989;29:240-5.